Crescent Biopharma (NASDAQ:CBIO – Get Free Report) and Corcept Therapeutics (NASDAQ:CORT – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
Volatility and Risk
Crescent Biopharma has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.
Insider and Institutional Ownership
75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by company insiders. Comparatively, 20.8% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Crescent Biopharma | N/A | -125.38% | -104.16% |
| Corcept Therapeutics | 12.96% | 15.19% | 11.93% |
Valuation & Earnings
This table compares Crescent Biopharma and Corcept Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crescent Biopharma | $10.84 million | 24.86 | -$153.94 million | ($14.21) | -1.37 |
| Corcept Therapeutics | $761.41 million | 5.94 | $99.65 million | $0.82 | 51.82 |
Corcept Therapeutics has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and price targets for Crescent Biopharma and Corcept Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crescent Biopharma | 1 | 0 | 5 | 3 | 3.11 |
| Corcept Therapeutics | 1 | 3 | 3 | 1 | 2.50 |
Crescent Biopharma currently has a consensus price target of $28.00, suggesting a potential upside of 44.33%. Corcept Therapeutics has a consensus price target of $77.67, suggesting a potential upside of 82.79%. Given Corcept Therapeutics’ higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Crescent Biopharma.
Summary
Corcept Therapeutics beats Crescent Biopharma on 10 of the 15 factors compared between the two stocks.
About Crescent Biopharma
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
